lunes, 14 de septiembre de 2026
Advancing Lymphoma Care With CAR T-Cell Therapies CME Thursday, 15 October 2026 | 12:00 PM - 12:45 PM ET | 18:00 - 18:45 CEST
https://na.eventscloud.com/website/98976/
Join our live, 45-minute webinar, "Advancing Lymphoma Care With CAR T-Cell Therapies," designed for hematology/oncology physicians, nurses, and pharmacists in the United States and Europe. Led by global experts, this session helps you safely integrate chimeric antigen receptor (CAR) T-cell therapies into your practice for B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). You will learn to navigate regional approvals and clinical data, streamline patient referrals and care handoffs, and manage toxicities like cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The webinar ends with a 15-minute live Q&A where you can ask the experts your questions directly.
Register now to help improve care and access for your patients. You will learn to navigate regional approvals and clinical data, streamline patient referrals and care handoffs, and manage toxicities like cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The webinar ends with a 15-minute live Q&A where you can ask the experts your questions directly. Register now to help improve care and access for your patients.
Here’s why separating MMR vaccines is a bad idea Teo Yik Ying | National University of Singapore | September 14, 2026
https://geneticliteracyproject.org/2026/09/14/heres-why-separating-mmr-vaccines-is-a-bad-idea/
Singapore has not been spared from the global resurgence of measles. As at end-July, Singapore had recorded 40 measles cases – the highest number in six years and already well above the total of 27 cases reported throughout 2025.
Fibermaxxing: Latest Instagram diet craze raises hope that a fiber-rich diet can improve health Claudia Steiner | September 14, 2026
https://geneticliteracyproject.org/2026/09/14/fibermaxxing-latest-instagram-diet-craze-raises-hope-that-a-fiber-rich-diet-can-improve-health/
In the world of dietary trends, proteinmaxxing is taking a back seat to the new obsession: ramping up on fiber. Since the summer of 2025, Instagram has racked up more than 10,000 posts captioned with #Fibermaxxing and other fiber-forward hashtags — and the flood doesn’t appear to be dissipating.
What cells can teach us about discovering better drugs By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short. Written byBree Foster, PhD
What cells can teach us about discovering better drugs
By tracking how cells respond to hundreds of thousands of compounds, Soley Therapeutics aims to discover medicines for complex diseases where traditional target-based approaches often fall short.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/what-cells-can-teach-us-about-discovering-better-drugs-17398?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9R6vF9OThDDgSzCXGjblX5fEa0lI7LbYo2XvB81mHcqC9hXkZdwfkHAuoaypaWH5yoSXYbJm7BdzIF2A9Wl4JzAEPpWg&_hsmi=438910159&utm_content=438910159&utm_source=hs_email
Modern drug discovery has become increasingly adept at identifying promising therapeutic targets. Advances in genomics, proteomics, and AI now allow researchers to sift through vast biomedical datasets to pinpoint proteins and pathways most likely to influence disease. Yet despite these advances, most drug candidates still fail in the clinic, often because the underlying biology proves more complex than anticipated.
You cannot understand biology by killing it Drug discovery still relies on destroying cells to understand how they respond, but new real-time measurement approaches are beginning to reveal biology in motion rather than in snapshots. Written byBree Foster, PhD May 11, 2026 | 5 min read
You cannot understand biology by killing it
Drug discovery still relies on destroying cells to understand how they respond, but new real-time measurement approaches are beginning to reveal biology in motion rather than in snapshots.
Written byBree Foster, PhD
May 11, 2026
https://www.drugdiscoverynews.com/you-cannot-understand-biology-by-killing-it-17159?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_92ADwkr17b9kR6cIm8jRhtvdR7Ezbyp0z15t8O-F_bP3qW3mr8-uKjmOAf-3hTg9US063U4ud68mgRxDESj1i5gaKCA&_hsmi=438910159&utm_content=438910159&utm_source=hs_email
Modern drug discovery is built on a paradox. To learn how living systems respond to intervention, we routinely destroy them. Cells are lysed, fixed, stained, sequenced, averaged, and reconstructed after the fact. This gives us a snapshot of what the cells were like before and after, but tells us very little about what happened in between.
What is a virtual cell? GenBio’s virtual cell integrates multiple layers of cellular biology to predict how cells respond to drugs and genetic changes. Written byBree Foster, PhD
What is a virtual cell?
GenBio’s virtual cell integrates multiple layers of cellular biology to predict how cells respond to drugs and genetic changes.
Written byBree Foster, PhD
https://www.drugdiscoverynews.com/what-is-a-virtual-cell-17525?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9sP9A8MsE5wkkXrNijSktusa-W1-fnV7Ucjm-IxJOFeIr50CYh_lpfH5TxMgItOeEVfruB9PL1ChSwzZogXSO-vDJVkw&_hsmi=438910159&utm_content=438910159&utm_source=hs_email
The idea of a virtual cell is not new. In the 1990s, genome scientist J. Craig Venter was already pursuing the idea of simulating an entire cell on a computer. His broader work — from helping pioneer rapid genome sequencing to creating organisms with synthetic genomes — helped lay the groundwork for thinking about biology as something that could be represented computationally.
Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann September 14, 2026, by Linda Wang
https://www.cancer.gov/news-events/cancer-currents-blog/2026/childhood-cancer-research-widemann?cid=eb_govdel
In recognition of Childhood Cancer Awareness Month, NCI's Dr. Brigitte Widemann discusses recent advances in treatment, shared data, artificial intelligence, research participation, and survivorship. She explains why sustained federal investment and partnerships with patients, families, advocates, and researchers are essential to continued progress.
Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT
https://na.eventscloud.com/website/98255/
This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia.
Am I a hypocrite for loving football despite CTE? Chronic traumatic encephalopathy has devastated generations of football players. Does that mean it’s unethical to be a fan?
https://www.statnews.com/2026/09/14/football-cte-risk-should-we-feel-guilty-for-watching-nfl/
By Michael ArkushSept. 14, 2026
Arkush has written or co-written 18 books, including New York Times best-sellers with Phil Jackson, Sugar Ray Leonard, and Scottie Pippen.
Definium’s LSD therapy eased anxiety in second large trial Company hopes to secure first approval of a psychedelic drug for anxiety By Elaine ChenSept. 14, 2026 National Biotech Reporter
https://www.statnews.com/2026/09/14/definiums-lsd-therapy-eased-anxiety-large-trial-psychedelic/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz--NVawLaBOypL8ocbG3c9BGCCvq1zsCwfHct913q1SnhV4ztQy7zUQmfvohBPSF65RVrNUyVb-89Zf7TCeQbTd5qYYKFA&_hsmi=438904019&utm_content=438904019&utm_source=hs_email
Definium's LSD treatment reduces anxiety
An LSD therapy from Definium Therapeutics significantly reduced anxiety in a second late-stage trial — setting the company up for perhaps the first approval of a psychedelic drug for anxiety, STAT’s Elaine Chen writes.
Patients who received a 100-microgram dose of DT120 saw their anxiety scores fall 9.8 points after 12 weeks, compared with 4.7 points for placebo — a 5.1-point difference similar to the company’s first pivotal study, according to newly released data.
About 32% of treated patients responded to therapy and 15% went into remission, versus 14% and 4% on placebo, respectively. Despite the positive readout, commercial hurdles remain: Patients would need to travel to clinics and spend as long as eight hours under supervision while receiving the drug. But Definium might have an advantage over psychedelic competitors focused solely on depression, since it is developing DT120 for both anxiety and depression, conditions that frequently overlap.
GLP-1s May Be Linked To Rare Brain Disorder Caused By B1 Deficiency
https://kffhealthnews.org/morning-briefing/monday-september-14-2026/
GLP-1s May Be Linked To Rare Brain Disorder Caused By B1 Deficiency
Although the study cannot prove that the medications caused the condition, researchers reported more cases of Wernicke encephalopathy in those taking GLP-1 medications than other drugs. Experts warn that while the drug shrinks your appetite, your body's requirements remain the same, which makes it easier for some people to suffer vitamin deficiencies, Fox News reported.
https://kffhealthnews.org/morning-breakout/pharmaceuticals-091426/
CLINICAL PERSPECTIVE (+++ +++ +++)
CLINICAL PERSPECTIVE
Data on Maribavir in Post-Transplant Cytomegalovirus
Neil Inhaber, MD, FRCPC, Therapeutic Area Head of Global Medical, Rare Disease at Takeda, discusses data on maribavir in post-transplant cytomegalovirus (CMV) presented at the American Transplant Congress 2026.
https://checkrare.com/data-on-maribavir-in-post-transplant-cytomegalovirus/
New Graves’ Disease Community Website
Christine Gustafson, Executive Director and CEO of the TED Community Organization, discusses the new Graves’ Community website.
https://checkrare.com/new-graves-disease-community-website/
Narcolepsy Diagnosis and Symptoms: Understanding the Daily Burden of the Disease
Tammy Anderson, Executive Director, and Jenny Rose, Manager of Outreach and Management at Wake Up Narcolepsy, discuss the challenges of diagnosing narcolepsy and the profound impact the disorder can have on patients and their families. Both Ms. Anderson and Ms. Rose are parents of children with narcolepsy.
https://checkrare.com/narcolepsy-diagnosis-and-symptoms-understanding-the-daily-burden-of-the-disease/
Kleefstra Syndrome: Development of RNA Amplifier Therapy
Eric Scheeff, PhD, Chief Scientific Officer at iDefine, discusses the treatment development of RNA amplifiers in patients with Kleefstra syndrome.
https://checkrare.com/kleefstra-syndrome-development-of-rna-amplifier-therapy/
Predicting Treatment Response Outcomes With Proteomic and Machine Learning Analyses in Myasthenia Gravis
Henry Kaminski, MD, Department of Neurology, and Linda Kusner, PhD, Department of Pharmacology & Physiology at George Washington University, discuss predicting response outcomes with proteomic and machine learning analyses in treating patients with myasthenia gravis (MG).
https://checkrare.com/predicting-treatment-response-outcomes-with-proteomic-and-machine-learning-analyses-in-myasthenia-gravis/
Making Travel Accessible: SMAshing My Limits Partners With Becoming rentABLE
Tracey Dawson, PhD, Senior Vice President, US Therapeutic Area Head Neuroscience at Novartis, discusses the collaboration between Novartis, SMAshing My Limits, and Becoming rentABLE, striving to make travel accessible.
https://checkrare.com/making-travel-accessible-smashing-my-limits-partners-with-becoming-rentable/
Addressing Patient Experiences With IgA Nephropathy
Gaia Coppock, MD, Nephrologist and Associate Professor of Clinical Medicine at the University of Pennsylvania, discusses patient experiences with IgA nephropathy (IgAN).
https://checkrare.com/addressing-patient-experiences-with-iga-nephropathy/
Patient Perspective: Diagnostic Journey With IgA Nephropathy
Byron Wade, a patient with IgA nephropathy (IgAN), discusses his personal diagnostic journey and a recent study looking at other patients’ experiences.
https://checkrare.com/patient-perspective-diagnostic-journey-with-iga-nephropathy/
Importance of Patient Listening in The Development of Rare Disease Treatments
Matt Trudeau, President of ITF Therapeutics, discusses the importance of patient listening in the development of Duvyzat (givinostat) for Duchenne muscular dystrophy (DMD).
https://checkrare.com/importance-of-patient-listening-in-the-development-of-rare-disease-treatments/
AI Tool Shows Promise for Assessing Pathologic Response in Lung Cancer Treatment
https://www.medscape.com/viewarticle/ai-tool-shows-promise-assessing-pathologic-response-lung-2026a1000xme?src=
An AI algorithm achieved 91% accuracy in assessing pathologic response (PR) to neoadjuvant chemoimmunotherapy in patients with non-small cell lung cancer (NSCLC), with performance consistent across four international cohorts. The AI-based percentage of residual viable tumour (%RVT) scoring showed at least moderate concordance with expert pathologist consensus, and discordant classifications occurred in fewer than 9% of cases.
9/11-Related Cancers Still Emerging 25 Years Later Alicia Ault September 14, 2026
https://www.medscape.com/viewarticle/sept-11-related-cancers-still-emerging-25-years-later-2026a1000xzg
Twenty-five years after the September 11 attacks, new data indicate that cancer diagnoses considered related to World Trade Center (WTC) exposure are continuing to emerge, highlighting the long latency of some malignancies associated with the disaster.
PARP Inhibitors for Prostate Cancer: 5 Things to Know Kate O'Rourke (+++ +++)
https://www.medscape.com/viewarticle/parp-inhibitors-prostate-cancer-5-things-know-2026a1000ocr?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312
Prostate cancer is the second most common cancer in men worldwide, with nearly 1.4 million new cases diagnosed each year. PARP inhibitors have transformed the treatment landscape for biomarker‑selected metastatic disease, moving from experimental agents to a core option for a subset of men with advanced prostate cancer. By exploiting defects in DNA repair — particularly homologous recombination repair (HRR) alterations such as BRCA1 and BRCA2 — these drugs can deliver meaningful survival gains after progression on standard hormone‑directed therapies. But their use is not one size fits all: benefit depends on tumor genomics, indications remain restricted to metastatic settings, and class‑specific toxicities such as anemia demand close monitoring and dose adjustment.
ArteraAI: Current Indications in Prostate Cancer
Suchandrima Bhowmik, MSc
https://www.medscape.com/viewarticle/arteraai-current-indications-prostate-cancer-2026a1000sow?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312
ArteraAI is a multimodal AI (MMAI) platform that integrates digitized hematoxylin and eosin (H&E) histopathology slide images with patient clinical variables, such as age, tumor stage, prostate-specific antigen and Gleason score, to predict personalized patient outcomes and treatment response across different types of prostate cancer.
ArteraAI is a multimodal AI (MMAI) platform that integrates digitized hematoxylin and eosin (H&E) histopathology slide images with patient clinical variables, such as age, tumor stage, prostate-specific antigen and Gleason score, to predict personalized patient outcomes and treatment response across different types of prostate cancer.
https://www.pluvicto-hcp.com/?utm_source=onlinearticle&utm_mlr=FA-11663924&utm_medium=display&utm_campaign=onlinearticle_branded_pr~plvb_ch~de_bu~on_yr~26_cu~hcp_id~b0004oc6_ca~b_ind~plupsm_cn~2026-pluvicto-hcp-de_jan-2026&utm_content=plu_prostate-cancer_awareness_biolumina_ms_mb~plui_ca~ub_cm~pluvictohcpunbrandedstaticbannerad6-26_sp~standard_cd~fa-11663924_ed~2027-01-31_id~cta_cr~gbs_ct~track_sz~300x250&utm_placement=id~d002vsow_pr~plvb_fm~beml_pd~coeenewsletter_ad~sstrac_dt~cross_vv~vp0dv_pb~medscape_sp~medscadg_da~na_btg~std_ind~plupsm_cu~hcp_ca~b_sz~1x1-mb~plui_ca~ub_cm~pluvictohcpunbrandedstaticbannerad6-26_sp~standard_cd~fa-11663924_ed~2027-01-31_id~cta_cr~gbs_ct~track_sz~300x250&utm_mdm=%25%25MDM_ID%25%25&dclid=CjgKEAjwtp7VBhCf153ftoqcl00SJABlQDcez4M4O8NtcYEH8oEFrUFGvIYznFWwFg8E0nHUuAUeZ_D_BwE&gad_source=7&gad_campaignid=23709534173
Choosing Wisely in Prostate Cancer: Tailoring Treatment for Men With Limited Longevity
Timothy J. Daskivich, MD, MSHPM; John T. Leppert, MD, MS
https://www.medscape.com/viewarticle/choosing-wisely-prostate-cancer-tailoring-treatment-men-2026a1000jp2?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312
Active Surveillance Rises as Focal Therapy Persists in Prostate Cancer
Frederik Joelving
https://www.medscape.com/viewarticle/active-surveillance-rises-focal-therapy-persists-prostate-2026a1000srp?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312
Do High-Risk Features of Prostate Cancer Boost Hormone Therapy Benefit?
Edited by Katie Lennon
https://www.medscape.com/viewarticle/do-high-risk-features-prostate-cancer-boost-hormone-therapy-2026a1000rop?ecd=MKMCMR_COE_260914_MSCPEDIT_Prostate-Cancer_etid8669312&uac=148436CN&impID=8669312
FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy?utm_medium=email&utm_source=govdelivery
FDA Approves First Therapy to Target Muscle Loss in
Spinal Muscular Atrophy
The U.S. Food and Drug Administration has approved Isembyld (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment.
Isembyld is the first approved SMA therapy to directly target muscle loss. Isembyld works by blocking myostatin, a protein that limits muscle growth, helping patients stabilize muscle and maintain greater muscle strength and function alongside their current treatment.
In a 52-week phase 3 clinical trial, patients treated with Isembyld showed statistically significant improvements in motor function compared to placebo and were more than twice as likely to achieve a clinically meaningful improvement in their ability to move and function (34.2% vs. 13.5%).
Isembyld carries a warning for an increased risk of fractures, including serious fractures. It may also cause fetal harm and affect reproductive function.
Isembyld was given Fast Track, Orphan Drug and Rare Pediatric Disease designations. The approval of Isembyld was granted to Scholar Rock, Inc.
domingo, 13 de septiembre de 2026
Probing the proteome at cellular scale Rapid technological advances are allowing researchers to identify thousands of proteins in individual cells, revealing the hidden mechanisms underlying development and disease. By Michael Eisenstein
https://www.nature.com/articles/d41586-026-02805-w?utm_source=Live+Audience&utm_campaign=38d7039c4f-nature-briefing-daily-20260907&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Probing the proteome at cellular scale
Cells that seem identical can have very different fates, thanks to the proteins they contain. But most analyses of single cells focus on the transcriptome to explore gene expression in the cell. Now a technique that many protein biologists thought was the stuff of science fiction has arrived with a bang: single-cell proteomics, which profiles thousands of proteins in individual cells. For example, in tumour cells, “single-cell proteomics may help us understand why patients have different outcomes due to tumour evolution, immune responses and cell differentiation — all driven by cellular heterogeneity”, says mass spectrometrist Yu-Ju Chen.
Revealed: inside the US military’s plan to tap huge sums from the NIH An agreement paves the way for hundreds of millions of dollars’ worth of projects to be transferred from the NIH’s institute for infectious diseases to the Department of Defense. By Max Kozlov
https://www.nature.com/articles/d41586-026-02799-5?utm_source=Live+Audience&utm_campaign=38d7039c4f-nature-briefing-daily-20260907&utm_medium=email&utm_term=0_-33f35e09ea-50432164
NIH strikes deal with Dept of Defense
The US National Institutes of Health (NIH) has signed an agreement with the US Department of Defense to redirect research projects worth hundreds of millions of dollars from its institute for infectious diseases to military biodefence programmes. The 10-year agreement would establish a pathway to move funding out of the NIH “on a project-by-project basis”, said an agency spokesperson in a statement. But some researchers worry that shifting biomedical research to the military threatens the transparency and clinical translation that define NIH-funded work.
Chronic Pain Treatment | Addressing ADHD | Blood Test for Alzheimer’s | Observing Community Diets | Research in Context
https://newsinhealth.nih.gov/
NIH Websites Are Changing
NIH is moving the launch of its new website to the fall to ensure the best possible experience for everyone who relies on our websites for health information, research, funding opportunities, and other resources.
Two children died from gene therapies in China: where the field goes next Strengthened laws should help to ensure future deaths are quickly disclosed to the public, but China’s reputation for such research is at risk. By Rachel Fieldhouse
https://www.nature.com/articles/d41586-026-02497-2?utm_source=Live+Audience&utm_campaign=4875bf78c7-nature-briefing-daily-20260908&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Gene-therapy deaths put spotlight on trials
The deaths of two children in separate gene-editing trials in China raise questions about oversight and could have a profound effect on the country’s biomedical industry, say researchers, ethicists and legal scholars. The two trials involved breaches of ethics and lacked transparency, and the deaths — one of which was only revealed after an investigation by Science and Retraction Watch — will probably prompt the introduction of stronger regulations for gene-therapy trials, researchers say. But a balance must be struck, says legal scholar Hank Greely. “We can’t make ethics so tight that no research can ever possibly be done,” he says.
Both trials fast-tracked as investigator-initiated trials (IITs). These enable researchers in China to test therapies quickly without supervision from the country’s drug regulator, and are widely considered to be a driving force behind China’s rising competitiveness in biomedicine. News of the deaths comes only months after the government introduced stricter rules for IITs of new biomedical technologies, which mandate that only certain hospitals may host such trials and which grant regulatory agencies the power to suspend or terminate trials if there are technical or ethical concerns.
China’s fast-track clinical trials are in the spotlight after child deaths
A new government policy seeks to balance innovation and safety.
By Xiaoying You
https://www.nature.com/articles/d41586-026-02407-6?utm_source=Live+Audience&utm_campaign=4875bf78c7-nature-briefing-daily-20260908&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Immune cells cross blood-brain barrier during human aging
Immune cells cross blood-brain barrier during human aging
At a Glance
Researchers found that some of the brain’s immune cells are replaced by immune cells from bone marrow as people age.
The findings suggest that scientists might one day be able to use immune cells born outside the brain to deliver therapies for brain disorders.
https://www.nih.gov/news-events/nih-research-matters/immune-cells-cross-blood-brain-barrier-during-human-aging
Scientists identify new role for tau protein in brain diseases
Scientists identify new role for tau protein in brain diseases
At a Glance
A study suggests that abnormal tau proteins involved in certain neurodegenerative diseases interact with mitochondria to drive a process called reverse electron transport.
Inhibiting this process may represent a new therapeutic strategy for brain diseases linked to abnormal tau.
https://www.nih.gov/news-events/nih-research-matters/scientists-identify-new-role-tau-protein-brain-diseases
Endometriosis may increase type 2 diabetes risk
Endometriosis may increase type 2 diabetes risk
At a Glance
Researchers found that some women with endometriosis may have increased risk of developing type 2 diabetes.
The study suggests premenopausal women with endometriosis but without obesity may benefit from earlier metabolic screening.
https://www.nih.gov/news-events/nih-research-matters/endometriosis-may-increase-type-2-diabetes-risk
Microbiome transplants may curb food allergies
Microbiome transplants may curb food allergies
At a Glance
Gut microbe transplants treated some peanut allergies in an early-stage clinical trial.
The results suggest changing a person’s microbiome using oral capsules may be a potential food allergy treatment.
https://www.nih.gov/news-events/nih-research-matters/microbiome-transplants-may-curb-food-allergies
Alzheimer's disease testing needs evidence, ethics, and equity The Lancet Neurology (++... ++)
Alzheimer's disease testing needs evidence, ethics, and equity
The Lancet Neurology
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00324-8/fulltext?dgcid=raven_jbs_etoc_email
Oct 2026
Volume 25Number 10p873-964, e14
https://www.thelancet.com/journals/laneur/issue/vol25no10/PIIS1474-4422(26)X2008-7
Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change
Prof Jonathan Graff-Radford, MDa Send email to graff-radford.jonathan@mayo.edu ∙ Prof Leah Karliner, MD MASc ∙ Prof Deborah E Barnes, PhD MPHd ∙ Prof Giovanni B Frisoni, MDe ∙ Prof Reisa Sperling, MDf ∙ Nicolas Villain, MD PhDg,h ∙ et al.
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00248-6/fulltext?dgcid=raven_jbs_etoc_feature_laneur
Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Prof Merit E Cudkowicz, MDa Send email to cudkowicz.merit@mgh.harvard.edu ∙ Prof Jeremy Shefner, MDb ∙ Prof Leonard H van den Berg, MDc ∙ Prof Adriano Chio, MDd,e ∙ Prof Dongsheng Fan, MDf ∙ Prof Julian Großkreutz, MDg,h ∙ et al.
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00277-2/fulltext?dgcid=raven_jbs_etoc_feature_laneur
Maintenance Warning: TheLancet.com will undergo planned maintenance on Monday, 14th September, from approximately 04:30 to 17:30 BST. During this time, some site functionality will be temporarily unavailable. We apologise for any inconvenience.
The long walk to antipsychotic availability The Lancet Psychiatry (++... ++)
The long walk to antipsychotic availability
The Lancet Psychiatry
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00278-6/fulltext?dgcid=raven_jbs_etoc_email
Oct 2026
Volume 13Number 10p811-904, e13
https://www.thelancet.com/journals/lanpsy/issue/vol13no10/PIIS2215-0366(26)X2008-9
The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial
Prof Christiane Montag, MDa Send email to christiane.montag@charite.de ∙ Anna-Lena Bröcker, Dr rer medica ∙ Samuel Bayer, Dr rer medica ∙ Katrin Becker, MAb ∙ Gianna Bertram, Dipl Psycha ∙ Marielle Büttner, MSca ∙ et al.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00240-3/fulltext?dgcid=raven_jbs_etoc_feature_lanpsy
Comparative effectiveness of mood stabiliser monotherapy versus second-generation antipsychotic monotherapy versus combination therapy for continuation and maintenance treatment after a first episode of psychotic mania in North America, Chile, and Spain: a target trial emulation using data from the BD-CAUSAL Collaboration
Alejandro G Szmulewicz, MD PhDa,b Send email to als1284@g.harvard.edu ∙ Yu-Hsin Liang, MD PhDa ∙ Gonzalo Martínez-Alés, MD PhDa,c ∙ Ryan O’Deaa ∙ Lorna E Thorpe, PhDd ∙ Sarah Conderino, DrPHd ∙ et al.
https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00239-7/fulltext?dgcid=raven_jbs_etoc_feature_lanpsy
Maintenance Warning: TheLancet.com will undergo planned maintenance on Monday, 14th September, from approximately 04:30 to 17:30 BST. During this time, some site functionality will be temporarily unavailable. We apologise for any inconvenience.
DeepMind’s new genome ‘atlas’ charts effects of all nine billion human gene mutations AI model AlphaGenome forecasts the consequences of altering every single DNA letter in the human genome. By Ewen Callaway
https://www.nature.com/articles/d41586-026-02835-4?utm_source=Live+Audience&utm_campaign=1ec0a93222-nature-briefing-daily-20260909&utm_medium=email&utm_term=0_-33f35e09ea-50432164
Mapping every single-DNA-letter change
The AI company Google DeepMind has released an ‘atlas’ of the human genome that aims to guide scientists through our biological code. The AlphaGenome Atlas charts the effects of nine billion single-DNA-letter changes — every possible mutation of this kind — in the human genome using predictions generated by a DeepMind AI model. The atlas could help to diagnose rare, unexplained diseases and uncover the hidden biology of common illnesses and biological traits, say researchers. It could also reveal some of the hidden rules by which DNA sequences control gene activity.
Frontiers of renal medicine: innovation, crosstalk, and sustainable restoration in chronic kidney disease Dolores Javier Sánchez-González* [1] , Nayeli Isabel Trejo-Bahena [2] , Enrique Méndez-Bolaina [3] , Israel Ramírez-Sánchez [1] , Elena de la Cruz Herrera-Cogco [3] , Gabriela Gutiérrez-Salmeán [4]
https://www.academia.edu/3070-3530/3/2/10.20935/AcadMedHealth8382
Chronic kidney disease (CKD) affects more than 850 million people worldwide, caused mostly by aging, diabetes, and hypertension. Current management remains focused on renal replacement therapies (RRT), such as dialysis and transplantation, with limited capacity for prevention or functional tissue regeneration. However, this paradigm has a limited impact on the progression of accelerated renal senescence and fails to prevent associated neurovascular complications, which contribute significantly to morbidity and mortality. To address these limitations, the present review examines an emerging therapeutic framework based on seven key areas: cellular senescence, the kidney–brain axis, onco-nephrology, nanonephrology, gene editing, xenotransplantation, and eco-nephrology. We discuss how the accumulation of senescent cells (p16INK4a+) promotes renal fibrosis, while the senescence-associated secretory phenotype (SASP) and uremic toxins propagate dysfunction throughout the neurovascular system. To address translational bottlenecks, a transition toward precision medicine is imperative, encompassing the deployment of nanocarriers that exploit the mesoscale paradox for direct delivery to the proximal tubule, alongside molecular repairs mediated by RNA interference and Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9 (CRISPR-Cas9). Additionally, 10-gene edited (10-GE) porcine xenotransplantation has emerged as a potential investigational strategy to address the critical shortage of available donor organs. Preliminary evaluations in human decedent models have already confirmed that these organs can sustain life-supporting functions. Finally, we discuss the high carbon footprint of renal care and define the principles of eco-nephrology through life cycle assessments. We conclude that renal medicine is gradually transitioning toward a proactive framework centered on prediction and restoration, which requires aligning novel biological tools with rigorous environmental metrics.
https://www.academia.edu/journals/academia-medicine-and-health/articles?source=journal-top-nav
Permeability to value in healthcare innovation procurements: a framework for design and assessment
Rossana Alessandrello, Victòria Valls-Comamala, Ion Arrizabalaga, Uxío Meis-Pinheiro, Olman Elizondo-Cordero, Ramon Maspons, Anna Garcia-Altés
It’s not 2020, but COVID is still a health threat Jess Steier | September 11, 2026
https://geneticliteracyproject.org/2026/09/11/its-not-2020-but-covid-is-still-a-health-threat/
Amom in my local parent group posted last week asking whether anyone else had recently had COVID. She’d just gotten over it, her seven-year-old had it now, and she said she hadn’t realized COVID was “still a thing.” Last I checked, the post had dozens of comments from parents expressing similar surprise. Gone are the days of 2020 and 2021, when we hung on every update, and I don’t think anyone wants those days back. But COVID is absolutely still around. So, is it surging right now, and what should our families do about it?
Leucovorin for autism: Prescriptions surged 700% after Trump endorsed “a random drug that probably doesn’t work” Meghan Holohan | September 11, 2026
https://geneticliteracyproject.org/2026/09/11/leucovorin-for-autism-prescriptions-surged-700-after-trump-endorsed-a-random-drug-that-probably-doesnt-work/
Following a White House press conference suggesting leucovorin as a treatment for autism in September 2025, and despite a lack of supporting data, US prescriptions of the drug soared, according to a paper published yesterday in The New England Journal of Medicine (NEJM).
5 years of The Lancet Regional Health – Americas Taissa Vila ∙ Gustavo Monnerat ∙ Orison Woolcott ∙ Maria Dario +... ++
5 years of The Lancet Regional Health – Americas
Taissa Vila ∙ Gustavo Monnerat ∙ Orison Woolcott ∙ Maria Dario
https://www.thelancet.com/journals/lanam/issue/vol61nonull/PIIS2667-193X(26)X2006-3
An echocardiographic appreciation of rheumatic heart disease: phenotypic variability of valvular involvement and its prognostic implications
Maria Carmo P. Nunesa,b Send email to mcarmo@waymail.com.br ∙ Pilly Chilloc,d ∙ Sheila Klassene ∙ Dorah Nampijjadf ∙ Fernanda de Azevedo Figueiredob ∙ Nayana Flamini Arantes Gomesa,b ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00196-1/fulltext?dgcid=raven_jbs_etoc_feature_lanam
Mobile intervention for emerging adults with regular cannabis use: a micro-randomized trial
Maureen Waltona,b,h,i ∙ Inbal Nahum-Shania,c,h,i ∙ Maya Campbella ∙ Devin C. Tomlinsona ∙ Autumn Rae Florimbioa ∙ Susobhan Ghoshd ∙ et al.
https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00154-7/fulltext?dgcid=raven_jbs_etoc_feature_lanam
Being seen: why authentic representation matters in rare disease care
https://rarerevolutionmagazine.com/being-seen-why-authentic-representation-matters-in-rare-disease-care/
Content developed and funded by Chiesi UK
Beyond the power of written communication, Dr Kamran Iqbal, Chiesi UK’s head of medical affairs and patient advocacy for global rare diseases, argues that the visibility of visual imagery is also a fundamental aspect of patient-centred care and health equity. In this Q&A, we explore the origins of the True Faces of Rare, a Chiesi UK initiative, and track its evolution from pledges to tangible action, and discuss the collective effort required to reshape visual representation across healthcare and policy
Contact Chiesi for more information here: https://www.chiesi.uk.com/contacts
https://www.chiesi.uk.com/contacts
Content developed and funded by Chiesi UK
UK-RD-2600104 | September 2026
Be Prepared to Identify and Manage Maternal Sepsis Karen Blum ++++
https://www.medscape.com/viewarticle/be-prepared-identify-and-manage-maternal-sepsis-2026a1000eiw?ecd=mkm_ret_260913_mscpmrk-OUS_ExcNews_etid8647919&uac=148436CN&impID=8647919
WASHINGTON, DC — While maternal sepsis is rare in the US, occurring in less than 1% of the sepsis population, it is responsible for 24% of intrapartum deaths and 38.4% of postpartum maternal deaths, said Andrea Shields, MD, professor and maternal-fetal medicine fellowship program director in the Department of Obstetrics and Gynecology at the University of Connecticut Health.
New Model's Accuracy Varies With Definition of Sepsis
Edited by Anushree Chaphalkar
https://www.medscape.com/viewarticle/new-models-accuracy-varies-definition-sepsis-2026a1000d0d?ecd=mkm_ret_260913_mscpmrk-OUS_ExcNews_etid8647919&uac=148436CN&impID=8647919
Non-Urinary Sepsis Linked to Higher Early Mortality in Nonagenarians and Centenarians
August 12, 2026
https://www.medscape.com/viewarticle/non-urinary-sepsis-linked-higher-early-mortality-2026a1000rk9?ecd=mkm_ret_260913_mscpmrk-OUS_ExcNews_etid8647919&uac=148436CN&impID=8647919
Rapid Sepsis Testing Can Save Lives and Curb Costs
Heidi Splete
https://www.medscape.com/viewarticle/rapid-sepsis-testing-can-save-lives-and-curb-costs-2026a1000eqi?ecd=mkm_ret_260913_mscpmrk-OUS_ExcNews_etid8647919&uac=148436CN&impID=8647919
sábado, 12 de septiembre de 2026
The Gustave Roussy-Lancet Lecture Series on Cancer Breakthroughs: Personalized Cancer Prevention Sept 18, 2026 5pm CEST In-person and online The Hive — Paris-Saclay Cancer Cluster, Villejuif, 94800, France
The Gustave Roussy-Lancet Lecture Series on Cancer Breakthroughs: Personalized Cancer Prevention
Sept 18, 2026
5pm CEST
In-person and online
The Hive — Paris-Saclay Cancer Cluster, Villejuif, 94800, France
https://gustaveroussy-lecture-series.com/?utm_medium=email&_hsenc=p2ANqtz-_5Y0rl65BJOgGWdih8S9w530-tM0zndSrpaW7UUezvQpr1e9eL7oKIRiam_T_BLeQ7CNsFnSHOoCicffeRhA-7jr8nCQ&_hsmi=438453448&utm_content=438365412&utm_source=hs_email
We are delighted to invite you to the inaugural Gustave Roussy-Lancet Lecture Series on Cancer Breakthroughs, delivered by Timothy R. Rebbeck. This Lecture is free to attend and will explore how precision medicine, polygenic risk scores, and population-level interventions are reshaping how we prevent — not only treat — cancer.
The Gustave Roussy-Lancet series of clinical oncology lectures brings together leading oncologists from around the world to present and discuss emerging concepts shaping the future of cancer care.
Nanoscope advances gene-agnostic therapy for severe vision loss in RP A failed RNA drug, major job cuts, a win for myeloma CAR T, and more led the news this week. Brought to you byDDN editorial team
Nanoscope advances gene-agnostic therapy for severe vision loss in RP
A failed RNA drug, major job cuts, a win for myeloma CAR T, and more led the news this week.
Brought to you byDDN editorial team
https://www.drugdiscoverynews.com/nanoscope-advances-gene-agnostic-therapy-for-severe-vision-loss-in-rp-17521
The FDA has accepted Nanoscope Therapeutics’ Biologics License Application for MOGENRY (sonpiretigene isteparvovec), an investigational optogenetic gene therapy for people with retinitis pigmentosa (RP) and severe vision loss. If approved, MOGENRY would be the first gene-agnostic treatment for this stage of RP, allowing patients to receive treatment independent of their individual mutation. RP encompasses more than 100 genes and more than 1,000 known mutations, creating a challenge for therapies designed around individual genetic causes. MOGENRY instead delivers a synthetic opsin gene to surviving bipolar retinal cells, making them sensitive to light after photoreceptor loss. The BLA is supported by positive results from the Phase 2b/3 RESTORE trial, which met its primary and key secondary endpoints for visual acuity at weeks 52 and 76, alongside longer-term data from the REMAIN follow-up study. – Bree Foster
Researchers design bone marrow-on-a-chip model to study human immune cells Miniaturized model provides window into production and behavior of long-lived antibody-producing cells in NIH-funded study.
Researchers design bone marrow-on-a-chip model to study human immune cells
Miniaturized model provides window into production and behavior of long-lived antibody-producing cells in NIH-funded study.
https://www.nih.gov/news-events/news-releases/researchers-design-bone-marrow-chip-model-study-human-immune-cells
U.S. Department of Health and Human Services
NATIONAL INSTITUTES OF HEALTH NIH News
National Institutes of Health
RESEARCHERS DESIGN BONE MARROW-ON-A-CHIP MODEL TO STUDY HUMAN IMMUNE CELLS
Miniaturized model provides window into production and behavior of long-lived antibody-producing cells in NIH-funded study
A scientific team funded by the National Institutes of Health (NIH) has developed a laboratory model that reveals how antibody-producing plasma cells migrate, mature, and survive within human bone marrow, a main location of long-lived antibody-producing plasma cells. The platform combines a lymph node mimicking organoid with a tissue chip that mimics bone marrow, allowing scientists to observe key stages of plasma cell development that have been difficult to study in humans. Analysis of the cells in the tissue chip provides essential new information that advances our understanding of plasma cell development and function. This model also supports testing of new therapies for infection prevention, inhibition of allergy, and reduction of autoimmunity. The study was published in Science Advances.
“This innovative bioengineering platform provides a window into a hidden aspect of the function of the human immune system” said John H. Powers III, M.D., acting director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID). “By emulating key elements of the immune system in this lymphoid and bone marrow-on-a-chip system, this tool provides opportunities to gather new insights that existing models do not offer.”
Plasma cells are an important component of the immune system. They produce antibodies that help protect against infections, but when antibody production goes awry, they can lead to autoimmune disease and allergy. If they proliferate excessively, they can also cause blood cancer. Long-lived plasma cells in the bone marrow are essential for maintaining antibody production and long-term immunity following infection or vaccination. However, how these cells migrate and settle into the bone marrow and how they are maintained in humans has remained poorly understood.
“Our approach has been working toward solving fundamental questions and advancing approaches to translate those findings,” said Ankur Singh, Ph.D., Carl Ring Family Professor of Bioengineering and the Director of Center for Immunoengineering at Georgia Tech, Atlanta. “A fundamental question our study addresses why it is that when B cells are ready to make antibodies, they relocate from lymph nodes, the spleen, and other organs and enter and take up residence in bone marrow. Another is a question of the role that the environment of bone marrow plays in orienting those cells and responses to reinfection.”
Singh leads the team at Georgia Tech that developed the human lymphoid organoid by isolating B cells from human tonsil tissue and blood sources and growing them in a microenvironment that mimics lymphoid tissue. In this phase of the research, they overcame challenges in culturing B cells and stimulating their transformation into antibody secreting plasma cells within the organoid, using inactivated influenza virus to spur the process. This method generated sufficient antibody-secreting plasma cells to use in their experiments with the bone marrow on a chip system.
The lab of Krishnendu Roy, Ph.D., Vanderbilt University, engineered the bone marrow chip using a complex microfluidics-based vascularized microenvironment that closely mimics conditions found in human bone marrow.
“We can never replicate the full complexity of the human body,” Roy said. “However, we are trying to mimic the structure, fundamental biological functions, and spatial microenvironments to ask questions about human organ-like behavior in this more simplified model.”
The human bone marrow-on-a-chip model is assembled within a three-by-five-inch stack of 96-well plastic plates, each less than half-an-inch thick. The chip interior is crisscrossed with multiple channels and coated with a gel-like material that is a facsimile of bone marrow and awash with nutrients and growth factors that support plasma cell function and maintenance. The layers of the chip structure correspond to an area at the outer edge of the bone marrow cavity, known as the endosteal subniche, where plasma cells are stored until called upon. The model also replicates an area deeper inside the center of the bone marrow, known as the perivascular subniche, that surrounds a network of blood vessels, where plasma cells proliferate and are activated.
The bone marrow chip system facilitates imaging of plasma cells to interpret their activity in response to signaling proteins. It also makes it possible to systemically study the effect of the various biological niches within the bone marrow on plasma cell differentiation and durability.
“It is nearly impossible to achieve high imaging resolution of plasma cells in living human bone marrow,” Singh said. “You can do some level of imaging in the bone marrow of a mouse, and so far that is what people have focused on.”
The organoid model can be seeded with cells from unique patient populations to study the effect of aging on plasma cell function, or people with autoimmune or allergic diseases to understand how autoimmunity or allergy-promoting plasma cells are produced and maintained. The researchers note that there are many questions they would still like to answer, such as why B cells exhibit a “stop-and-go” pattern of movement and whether this pattern of movement is part of a constant migration within the broader bone marrow structure.
This research was funded in part by NIAID under R01AI186314 and R01AI181282 and by the National Institute of General Medical Sciences (NIGMS) grant T32GM145735.
NIAID conducts and supports research to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office
---
REFERENCES: L Kramer et al. Ex Vivo Bone Marrow Subniches Influence the Fate of Human Antibody-Secreting Cells. Science Advances:
###
This NIH News Release is available online at:
Burden of cardiovascular diseases in the Asia–Pacific region from 1990 to 2023, with forecasts to 2050: a secondary analysis of the Global Burden of disease study 2023 Nicholas W.S. Chewa,b,aa ∙ Srinithy Nagarajana,c,aa ∙ F Aaysha Caderd,e ∙ Yiming Chena ∙ Bryan Chonga ∙ Clara K. Chowf ∙ et al.
Burden of cardiovascular diseases in the Asia–Pacific region from 1990 to 2023, with forecasts to 2050: a secondary analysis of the Global Burden of disease study 2023
Nicholas W.S. Chewa,b,aa ∙ Srinithy Nagarajana,c,aa ∙ F Aaysha Caderd,e ∙ Yiming Chena ∙ Bryan Chonga ∙ Clara K. Chowf ∙ et al.
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(26)00139-2/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-_i4lVJFI7M4AADuRUB2vvsMZascltJIpHL1TofgQEEDZGu8GYjAuFZ0PROPBbgOgk7E-nIsP35yssjBxP3NpAzspDlSA&_hsmi=438630108&utm_content=438569947&utm_source=hs_email
Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Second-hand smoke Collaborators
Global, regional, and national prevalence of second-hand smoke and attributable disease burden in 204 countries and territories, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
GBD 2023 Second-hand smoke Collaborators
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00168-4/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-9TqVOrJraIXfMkPPaRAe93Z2xwUJwqCy3bqjycEuZdpP6ZKd08nX7HB31unMVvp63krlgX1c9XRzd3c9MfGaC9LPMvLA&_hsmi=438630108&utm_content=438569947&utm_source=hs_email
Burden of Dementia in Europe, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 Daniele Ursoa,b Send email to daniele.urso@etu.unige.ch ∙ Emma Nicholsc,d ∙ Stefano Giannoni-Luzaa,e ∙ Carol Braynef ∙ Nicolas Rayb ∙ Giancarlo Logroscino
Burden of Dementia in Europe, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023
Daniele Ursoa,b Send email to daniele.urso@etu.unige.ch ∙ Emma Nicholsc,d ∙ Stefano Giannoni-Luzaa,e ∙ Carol Braynef ∙ Nicolas Rayb ∙ Giancarlo Logroscino
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00208-5/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-8A8peMnoWinLAvrxqjz8UUIAGHmpLTyGWccQghedj7AgZSTlHx_4w6g-FZNpysbW5Dv9wLyCS7yjhTiRF9mfB7iJ6fvA&_hsmi=438630108&utm_content=438569947&utm_source=hs_email
Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 Prof Simon I Hay, DSca,b Send email to sihay@uw.edu ∙ Paul Nam, MSa ∙ Haaris Saqib, MAa ∙ Susan A McLaughlin, PhDa ∙ Catherine Bisignano, MPHa ∙ Samuel M Ostroff, PhDa,c ∙ et al.
Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
Prof Simon I Hay, DSca,b Send email to sihay@uw.edu ∙ Paul Nam, MSa ∙ Haaris Saqib, MAa ∙ Susan A McLaughlin, PhDa ∙ Catherine Bisignano, MPHa ∙ Samuel M Ostroff, PhDa,c ∙ et al.
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00098-8/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-_37FZrYSEuEyGjXtXH6Ox57vee2AWUhIBQ6k9OxXfrA5euYoo4HfU9W8mm6_70tFFcuCPGvCIPs03uwkP28D2qOv3AQg&_hsmi=438630108&utm_content=438569947&utm_source=hs_email
Global, regional, and national burden of road injuries 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Road Injuries Collaborators
Global, regional, and national burden of road injuries 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
GBD 2023 Road Injuries Collaborators
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00141-6/fulltext?dgcid=hubspot_email_lancet-gbdalerts&utm_campaign=gbdalerts&utm_medium=email&_hsenc=p2ANqtz-_-VlEjEs28GycBAXbF_u6yu3N94LjENfp1r8JzFMXy1G7gfw1oIg9eftKB0e5dWDZy3bfNiDNwGpPNkSgtBqcz21M92A&_hsmi=438630108&utm_content=438569947&utm_source=hs_email
ER-Positive/HER2-Negative Metastatic Breast Cancer: Navigating Endocrine Resistance and Expanding Treatment Options (+... videos +++++)
New Resources Available: ER+/HER2−- Metastatic Breast Cancer: Navigating Endocrine Resistance and Expanding Treatment Options
ER-Positive/HER2-Negative Metastatic Breast Cancer: Navigating Endocrine Resistance and Expanding Treatment Options
Endocrine therapy remains the cornerstone of treatment for ER-positive/HER2-negative metastatic breast cancer, yet both intrinsic and acquired resistance ultimately limit its long-term success. Resistance arises through diverse mechanisms—including activating ESR1...
https://www.medscape.org/advances/oral-serds-2025a1000o90?src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection
Authors:
Joyce A. O’Shaughnessy, MD; Aditya Bardia, MD, MPH, FASCO
https://www.medscape.org/viewarticle/1003008?src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition
Authors: Kelly Shanahan, MD; Sara Tolaney, MD, MPH; Virginia Kaklamani, MD, DSc; Sarah R. Donahue, MPH, NP, AOCNP; Abigail Shockley, PharmD, BCOP
https://www.medscape.org/viewarticle/communicating-enhance-care-through-data-and-patient-2025a1000uqi?page=1&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC
Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD
https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
Current and Future Oral SERD Strategies in the Management of ER-Positive/HER2-Negative MBC: Analyzing the Clinical Data
Authors: Komal Jhaveri, MD, FACP, FASCO; Shaheenah Dawood, MD, MPH
https://www.medscape.org/viewarticle/current-and-future-oral-serd-strategies-management-er-2026a100022b?page=1&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
Patients Progressing on an AI ± CDK4/6 Inhibitors: From Biomarkers to Treatment Strategies
Authors: Manali Bhave, MD; Nadia Harbeck, MD, PhD
https://www.medscape.org/viewarticle/patients-progressing-ai-cdk4-6-inhibitors-biomarkers-2025a1000wtp?page=1&src=mkmcmr_driv_32025_mscpedu_437674.35_ace_final&uac=148436CN
viernes, 11 de septiembre de 2026
People with ADHD face higher odds of gastrointestinal problems
https://www.news-medical.net/news/20260910/People-with-ADHD-face-higher-odds-of-gastrointestinal-problems.aspx
University of Warwick researchers have analyzed data from over 1.9 million people across 23 studies and found that ADHD is linked to an almost 50% increase in overall gastrointestinal symptoms compared with people without ADHD The association was even stronger for specific problems: nearly double the odds of constipation, a 58% increase in irritable bowel syndrome, and more than four times the odds of encopresis (loss of bowel control).
An estimated 5% of children and 3-4% of adults have ADHD worldwide and reported diagnosis rates have risen sharply over the past 40 years. Gut problems are already well documented in autism spectrum disorder, with a growing body of evidence pointing to a 'gut-brain axis' linking digestive health to neurodevelopmental conditions more widely. Until now, the extent of gastrointestinal symptoms in people with ADHD has remained unclear.
Early studies hint that ketones may affect pathways linked to PTSD
https://www.news-medical.net/news/20260911/Early-studies-hint-that-ketones-may-affect-pathways-linked-to-PTSD.aspx
From altered brain energy metabolism to inflammation and neurotransmitter signaling, researchers examine why raising ketone levels has drawn interest as a potential metabolic approach to PTSD.
In a recent integrative review published in the journal Frontiers in Psychiatry, researchers evaluated the potential of ketogenic therapy as a treatment for post-traumatic stress disorder (PTSD), including evidence concerning efficacy, mechanisms, safety, and feasibility.
AI identifies hidden biological patterns to accurately diagnose migraines
https://www.news-medical.net/news/20260911/AI-identifies-hidden-biological-patterns-to-accurately-diagnose-migraines.aspx
AI can trawl vast amounts of health data which is not specifically related to migraines, but which can be used to identify people predisposed to the condition.
A new study from NTNU - the Norwegian University of Science and Technology - reveals that migraines may leave a biological pattern throughout the body, traces of which can be identified by artificial intelligence.
Proteomic signatures reveal early signs of cardiovascular-kidney-metabolic disease in children
https://www.news-medical.net/news/20260911/Proteomic-signatures-reveal-early-signs-of-cardiovascular-kidney-metabolic-disease-in-children.aspx
Researchers at Vanderbilt Health, UTHealth Houston and the University of North Carolina at Chapel Hill have identified early signs of cardiovascular-kidney-metabolic disease (CKMD) in children as young as 8 years old that potentially can be reversed with a new class of weight loss drugs used widely by adults.
Using cutting-edge analytic techniques, the researchers defined a "signature" of circulating proteins in children and adolescents that mirrored the molecular biomarkers associated with irreversible cardiovascular disease in adults.
Cancer treatments alter the landscape of genetic mutations in healthy body tissues
https://www.news-medical.net/news/20260911/Cancer-treatments-alter-the-landscape-of-genetic-mutations-in-healthy-body-tissues.aspx
Cancer treatments, including chemotherapy and radiotherapy, give a growth advantage to cells with particular genetic changes in healthy tissue, new research finds.
Researchers from the Wellcome Sanger Institute, University of Cambridge, University College London and their collaborators used DNA sequencing to map the mutations in normal esophagus tissue from esophageal cancer patients who had received either chemotherapy, chemotherapy and radiotherapy, or no treatment before surgery.
Neighborhood environments impact long-term health of 9/11 responders
https://www.news-medical.net/news/20260911/Neighborhood-environments-impact-long-term-health-of-911-responders.aspx
Twenty-five years after the September 11 terrorist attacks, researchers at the Icahn School of Medicine at Mount Sinai have found that environmental conditions where World Trade Center responders live may influence their long-term physical and mental health.
Published in Nature Communications, the study found an association between responders exposed to higher temperatures and greater levels of air pollution and an increased risks of frailty, post-traumatic stress disorder (PTSD), and depression as they aged. In contrast, living in greener environments was associated with lower risks of all three conditions.
Risk factors for cardiovascular-kidney-metabolic disease can be identified in young children
https://www.news-medical.net/news/20260911/Risk-factors-for-cardiovascular-kidney-metabolic-disease-can-be-identified-in-young-children.aspx
Risk factors for cardiovascular-kidney-metabolic disease, a health condition made up of heart disease, kidney disease, diabetes, and obesity, can be identified in children as young as 8, UTHealth Houston researchers discovered.
Using a group of 273 children who participate in the Border Health Research Cohort within the Border Health Research Center at UTHealth Houston School of Public Health in Brownsville, researchers analyzed 5,000 proteins and identified six "signatures" of proteins that significantly influence the risk of developing cardiovascular-kidney-metabolic disease in adulthood. The same protein signature was present in 685 adults from the same community who were at high risk of irreversible cardiovascular-kidney-metabolic disease, according to the team.
Early treatment significantly reduces joint damage in rheumatoid arthritis
https://www.news-medical.net/news/20260911/Early-treatment-significantly-reduces-joint-damage-in-rheumatoid-arthritis.aspx
Early and consistently managed treatment can have a decisive impact on the course of rheumatoid arthritis and prevent permanent joint damage. An international review led by Josef S. Smolen of the Medical University of Vienna highlights which diagnostic and therapeutic measures are crucial a good outcome in patients with this disease, based on the current state of research. The analysis, published in the leading journal JAMA, summarises the evidence on the aetiology, diagnosis, treatment and prognosis of the disease.
Five minutes of coffee aroma was linked to shifts in mood and brain activity
https://www.news-medical.net/news/20260910/Five-minutes-of-coffee-aroma-was-linked-to-shifts-in-mood-and-brain-activity.aspx
Researchers tracked mood, brain activity, heart rate, and autonomic signals in the same young adults to examine how the mind and body respond to just five minutes of coffee aroma.
A recent study in the journal Nutrients examined electroencephalographic (EEG) activity, subjective mood, heart rate (HR), and heart rate variability (HRV) following short-term exposure to the aroma of coffee, using a multi-modal approach.
Perilla frutescens Benefits: Effects on Allergy, Inflammation, Immunity, and Gut Health ++ +...
Perilla frutescens Benefits: Effects on Allergy, Inflammation, Immunity, and Gut Health
https://www.news-medical.net/health/Perilla-Frutescens-Benefits-Effects-on-Allergy-Inflammation-Immunity-and-Gut-Health.aspx
What happens when compounds from an ancient East Asian herb encounter mast cells, regulatory T cells, intestinal barriers, and the gut microbiome? Emerging research is beginning to map how Perilla may influence these interconnected systems, and the evidence still leaves important questions unanswered.
This article discusses the latest clinical and preclinical research on the anti-inflammatory effects of Perilla frutescens and its potential relevance to allergic inflammation, immune regulation, and gastrointestinal health
Traditional Inuit Diet: Foods, Nutrition, and Health Effects
https://www.news-medical.net/health/Traditional-Inuit-Diet-Foods-Nutrition-and-Health-Effects.aspx
From vitamin-rich country foods to rapidly expanding market-food consumption, research across Inuit communities reveals a complex nutritional transition shaped by culture, physical activity, food security, and a changing Arctic.
For centuries, Inuit populations have thrived in one of Earth's most extreme environments by relying on nutrient-dense animal-rich diets incorporating marine and terrestrial country foods. This traditional dietary pattern reflects thousands of years of adaptation to the Arctic and provides valuable insights into the health effects of replacing ancestral foods with modern processed alternatives.
https://www.news-medical.net/medical/articles
How Mental Health Influences Bladder Function and Lower Urinary Tract Symptoms
https://www.news-medical.net/health/How-Mental-Health-Influences-Bladder-Function-and-Lower-Urinary-Tract-Symptoms.aspx
From chronic stress and altered sensory processing to anxiety and depression, emerging evidence is revealing an intricate relationship between the mind and the lower urinary tract - and challenging how bladder disorders are understood and managed.
Chronic psychological stress can affect lower urinary tract function, with animal models demonstrating changes in bladder sensitivity and voiding, while human studies consistently report associations between lower urinary tract symptoms (LUTS), anxiety, and depression.2,4,5 These relationships appear to be bidirectional in some longitudinal studies, although causality has not been established across the broader literature.
Xylitol Linked to Increased Long-Term Cardiovascular Risk Aude Lecrubier
https://www.medscape.com/viewarticle/xylitol-linked-increased-long-term-cardiovascular-risk-2026a1000x7i?ecd=WNL_trdalrt_pos1_ous_260911_etid8682439&uac=148436CN&impID=8682439
MUNICH — A large German study presented at the European Society of Cardiology (ESC) Congress 2026 showed that high blood levels of xylitol — a widely used natural sweetener also known as “birch sugar” — were associated with an increased long-term risk for major adverse cardiovascular events in the general population.
Erdheim-Chester Disease by Madaline Spencer| Published on: Aug 15, 2024
Erdheim-Chester Disease
by Madaline Spencer| Published on: Aug 15, 2024
Erdheim-Chester disease (ECD) is a rare condition affecting many parts of the body. Although diagnosed in some children, it most commonly affects adults. ECD causes the overproduction of histiocytes, which then accumulate in tissues and organs. Parts of the body that may be involved include the long bones, retroperitoneum, skin, eyes and eyelids, lungs, brain, heart, kidneys, and pituitary gland. However, various other tissues or organs can be affected.
https://checkrare.com/erdheim-chester-disease-2/
Father Pursues Gene Therapy for Sons With Rare Genetic Variations of Duchenne Muscular Dystrophy by Madaline Spencer| Published on: Sep 11, 2026
Father Pursues Gene Therapy for Sons With Rare Genetic Variations of Duchenne Muscular Dystrophy
by Madaline Spencer| Published on: Sep 11, 2026
Tushar Tangsali, father to two sons with Duchenne muscular dystrophy (DMD), discusses how he’s working to develop a gene therapy for a unique genetic variation of DMD for his sons.
https://checkrare.com/father-pursues-gene-therapy-for-sons-with-rare-genetic-variations-of-duchenne-muscular-dystrophy/
Increased Dosing Interval of Mogamulizumab in Patients With CTCL by CheckRare Staff| Published on: Jul 20, 2026
Increased Dosing Interval of Mogamulizumab in Patients With CTCL
by CheckRare Staff| Published on: Jul 20, 2026
Christiane Querfeld, MD, PhD, dermatologist and and Director, Multidisciplinary Cutaneous Lymphoma Program, Professor at the City of Hope National Medical Center and the Beckman Research Institute, discusses the results of a new drug trial that increased the dosing interval of mogamulizumab in patients with CTCL.
https://checkrare.com/increased-dosing-interval-of-mogamulizumab-in-patients-with-ctcl/
Bad Behaviors … Good Parenting? By Ivanhoe Broadcast News on September 17, 2026
Orlando, Fla. (Ivanhoe Newswire) — In a recent survey, people with young kids said they feel like “bad” parents around three times a week, which totals 156 times a year! the pressure to be a good parent is real. but experts say your child’s behavior might not always be the best measure of how well you’re doing. Parenting
https://www.ivanhoe.com/?p=37603&preview=1&_ppp=ea8b170ae6
De-Brand Your Life: Stop Living for the Feed By Ivanhoe Broadcast News on September 16, 2026
Orlando, Fla. (Ivanhoe Newswire) — The average person now spends several hours each day on social media. Today, just about everything can become content. Your workout, your vacation, your dinner, your family. But some experts say constantly thinking about what to post, instead of simply being present, may be creating a new kind of burnout.
https://www.ivanhoe.com/?p=37600&preview=1&_ppp=f2e91fb16d
Suicide Prevention: The Silent Warning By Ivanhoe Broadcast News on September 15, 2026
Orlando, Fla. (Ivanhoe Newswire) — September is Suicide Prevention Month. Last year, nearly 49,300 Americans died by suicide, and the CDC says more than 13 million adults seriously considered suicide. Mental health experts say one of the biggest warning signs isn’t always what people say, it may be what they stop saying.
https://www.ivanhoe.com/?p=37595&preview=1&_ppp=b8a95e837f
College Job Scams: Beware! By Ivanhoe Broadcast News on September 14, 2026
Orlando, Fla. (Ivanhoe Newswire) — Back to school means college students are heading back to campus, and many are also looking for jobs and internships. But scammers are looking for them. Reports of employment scams doubled in 2025 and about one in three Gen Z job seekers say they’ve fallen victim to a job scam.
https://www.ivanhoe.com/?p=37590&preview=1&_ppp=32d4ac76cc
Grandparents Day: Conversations That Matter By Ivanhoe Broadcast News on September 13, 2026
Orlando, Fla. (Ivanhoe Newswire) — Grandparents Day is Sunday, September 13th. More than 65 million Americans are grandparents, and AARP says they spend more than 500 hours a year caring for their grandchildren. Those hours are about more than babysitting for many families, they’re where family stories are told, traditions are passed down, and life lessons are shared. But we wondered if grandparents could leave their grandchildren with just one message, what would it be?
https://www.ivanhoe.com/?p=37593&preview=1&_ppp=536adac9db
jueves, 10 de septiembre de 2026
Con game: What happens when people are overly concerned they may be suckered Greg Miller | September 10, 2026 (+++)
Con game: What happens when people are overly concerned they may be suckered
Greg Miller | September 10, 2026
https://geneticliteracyproject.org/2026/09/10/con-game-what-happens-when-people-are-overly-concerned-they-may-be-suckered/
From smart packaging to bio-based coatings, scientists find new ways to reduce food contamination
Mariella Bodemeier Loayza Careaga | September 8, 2026
https://geneticliteracyproject.org/2026/09/08/from-smart-packaging-to-bio-based-coatings-scientists-find-new-ways-to-reduce-food-contamination/
Allergic to dogs? A CRISPR solution may be in the works
Laura Dattaro | September 10, 2026
https://geneticliteracyproject.org/2026/09/10/allergic-to-dogs-a-crispr-solution-may-be-in-the-works/
Science Literacy Project Daily Digest Science Controversies in the Media (++++ ++++)
Science Literacy Project Daily Digest
Science Controversies in the Media
Facing ridicule, Hegseth rescinds Pentagon’s new testosterone mandates
ABC News
https://geneticliteracyproject.org/2026/09/10/facing-ridicule-hegseth-rescinds-pentagons-new-testosterone-mandates/
Chemophobia trap: How the ‘appeal to nature’ fallacy makes ‘clean’ and organic products seem safer—even when they’re not
Huffington Post
https://geneticliteracyproject.org/2026/09/10/chemophobia-trap-how-the-appeal-to-nature-fallacy-makes-clean-and-organic-products-seem-safer-even-when-theyre-not/
Flattening culture and cognition: Is AI eroding our singularity?
Nature
https://geneticliteracyproject.org/2026/09/10/flattening-culture-and-cognition-is-ai-eroding-our-singularity/
Viewpoint: Cocky but wrong—feeling superior feeds medical and health conspiracy theories
Glendale Star
https://geneticliteracyproject.org/2026/09/10/viewpoint-cocky-but-wrong-feeling-superior-feeds-medical-and-health-conspiracy-theories/
Social media still eclipses AI as the driving force of medical misinformation
Tech Target
https://geneticliteracyproject.org/2026/09/09/social-media-still-eclipses-ai-as-the-driving-force-of-medical-misinformation/
Public is skeptical about claims of vaccine danger, but a poll shows troubling doubts
Laine Bergeson | CIDRAP
https://geneticliteracyproject.org/2026/09/09/public-is-skeptical-about-claims-of-vaccine-danger-but-a-poll-shows-troubling-doubts/
The promise and peril of gene editing
MedPage Today
https://geneticliteracyproject.org/2026/09/09/the-promise-and-peril-of-gene-editing/
Viewpoint: How to challenge the lucrative health fear-mongering business
STAT News
https://geneticliteracyproject.org/2026/09/09/viewpoint-how-to-challenge-the-lucrative-health-fear-mongering-business/
Lead Generation and Aligning Sales and Marketing: What’s Changed, What's Working, What's Not, and Best Practices September 29th, 2026 at 9:00 am PDT / 12:00 pm EDT / 5:00 pm BST / 6:00 pm CEST
https://pages.labxmediagroup.com/lead-generation-and-aligning-sales-and-marketing?hsCtaAttrib=220282661392
Lead generation in the life sciences isn't broken—but the landscape has changed significantly, and many of the standard practices haven't kept pace. How prospects prefer to communicate is different: increasingly, people want to be reached via SMS, WhatsApp, and other modern channels that many commercial sales teams don't routinely use. Standard modes of follow-up aren't inherently flawed—they're simply no longer aligned with how today's buyers operate.
As a result, vendors are losing pipeline at multiple stages: in campaign and landing page configuration, in the qualification criteria applied before a lead is even accepted, in lead classification, and in what happens after the form is filled—which, too often, is not enough. Too few sales reps make a concerted effort to follow up with the consistency that converting a lead requires. The fallout is a widening divide between sales and marketing: marketing generates leads it considers legitimate, sales dismiss them as low quality, and prospects—unreached through the right channels—simply don't respond.
In this panel discussion, experts from LabX Media Group and JBC Associates draw on data from thousands of campaigns and decades of frontline commercial experience to examine common mistakes and practical fixes across the full lead generation journey.
Why the best drug candidates get missed by narrow screens Starting from a defined mechanism can cause discovery programs to miss the best drug candidates. Written byAndrea Corona
Why the best drug candidates get missed by narrow screens
Starting from a defined mechanism can cause discovery programs to miss the best drug candidates.
Written byAndrea Corona
https://www.drugdiscoverynews.com/why-the-best-drug-candidates-get-missed-by-narrow-screens-17494?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-98Glw7Y64mq7yYTRtyw4rkIvPngGYLswQIhomzYmmP3l39q-xE8eFGrJcFoJSZh9fOi3umPOuFHL0-6K6kK4gWfHEFew&_hsmi=438341142&utm_content=438341142&utm_source=hs_email
Most degrader discovery programs start with a hypothesis: pick the target, pick the E3 ligase, pick a binding pocket, then screen for a molecule that connects them. Matthias Brand, cofounder and Chief Technology Officer of Proxygen, told DDN that approach can cause programs to miss their best candidates before they're found.
Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas by Madaline Spencer| Published on: Aug 14, 2026
Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas
by Madaline Spencer| Published on: Aug 14, 2026
Alexandra Miller, MD, PhD, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at the Perlmutter Cancer Center at NYU Langone Health, discusses follow-up data on the safety and efficacy of safusidenib in patients with IDH-mutant gliomas.
https://checkrare.com/follow-up-data-of-safusidenib-in-patients-with-idh-mutant-gliomas/
Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4 Ab+ and Triple Seronegative Myasthenia Gravis
https://checkrare.com/learning/p-beyond-achr-recognizing-and-treating-musk-ab-lrp4-ab-and-triple-seronegative-myasthenia-gravis/
This accredited CME program examines best practices to diagnose and treat patients with ultra-rare forms of myasthenia gravis.
The most prevalent form of myasthenia gravis is associated with antibodies against the acetylcholine receptor (AChR Ab+). However, 15- 20% of patients with myasthenia gravis are not AChR Ab+. These clinically important and underrecognized subsets of patients harbor antibodies against muscle-specific kinase (MuSK Ab+) lipoprotein receptor-related protein 4 (LRP4 Ab+), or test negative for all known antibodies (triple seronegative MG). These patients present unique diagnostic and treatment challenges that necessitate expert guidance to improve their management.
Suscribirse a:
Entradas (Atom)
